Substance Use Disorders

Study Notes

SECTION 1: CLASSIFICATION OF SUBSTANCE USE DISORDERS

1.1 Conceptual Framework

Substance use disorders exist on a spectrum from use → misuse → harmful use → dependence. The major diagnostic systems differ in how they carve this spectrum.

1.2 ICD-11 Classification

Categories under "Disorders due to substance use" (6C40–6C4Z):

Swipe to compare →

ICD-11 Dependence Criteria (3 or more features present together):

1. Strong internal drive / compulsion to use
2. Impaired control (onset, frequency, amount, cessation)
3. Priority given to use over other activities and obligations
4. Use despite harm (physical, mental, social)
5. Tolerance
6. Withdrawal symptoms OR use to avoid withdrawal
7. Physiological features (tolerance + withdrawal = physiological dependence subtype)

1.3 DSM-5 Classification

DSM-5 collapsed the old Abuse / Dependence distinction into a single spectrum disorder with mild/moderate/severe specifiers.

DSM-5 Substance Use Disorder Criteria (11 criteria across 4 domains):

Severity:

• Mild: 2–3 criteria
• Moderate: 4–5 criteria
• Severe: 6+ criteria

1.4 ICD-11 vs DSM-5: Key Differences

1.5 Physical vs Psychological Dependence

SECTION 2: ALCOHOL USE DISORDER

2.1 Epidemiology

• Global: ~2.3 billion drinkers; 283 million with AUD (WHO 2018)
• India: ~160 million drinkers; alcohol accounts for ~4% of global disease burden
• Male:Female ratio India: ~10:1 (changing)
• NMHS India 2016: Alcohol use disorders 4.6% lifetime prevalence

2.2 Pharmacology of Alcohol

Primary mechanism: Potentiation of GABA-A receptors + Inhibition of NMDA glutamate receptors

2.3 Metabolism of Alcohol

Pathway:

Key facts:

Disulfiram mechanism: Inhibits ALDH → acetaldehyde accumulates → flushing, nausea, palpitations, hypotension (disulfiram-ethanol reaction / DER).

2.4 Alcohol Withdrawal

Timeline:

2.5 Delirium Tremens (DTs)

Clinical features (5 Ds):

• Delirium (confusion, disorientation, impaired attention)
• Diaphoresis (profuse sweating)
• Dysautonomia (tachycardia, hypertension, hyperthermia, mydriasis)
• Dread (extreme anxiety, agitation)
• Dreams / hallucinations (visual > auditory; Lilliputian hallucinations classic)

Risk factors for severe withdrawal:

• Previous severe withdrawal / seizures / DTs
• High alcohol intake (>10 drinks/day)
• Long duration of dependence
• Old age
• Concurrent medical illness
• Poor nutrition (thiamine deficiency)
• Benzodiazepine/sedative co-use

2.6 CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, revised)

10 items assessed:

Total score interpretation:

2.7 Management of Alcohol Withdrawal

Step 1: Assess and stabilize

• Vitals, blood glucose, electrolytes (Na, K, Mg), LFTs, CBC, coagulation
• Identify concurrent illness, head injury, infection
• Assess nutritional status, hydration

Step 2: Thiamine (MANDATORY, before any glucose/IV fluids)

• 100 mg IV/IM thiamine before glucose infusion
• Rationale: Glucose load can precipitate Wernicke's encephalopathy in thiamine-depleted state
• High-risk patients: 200–500 mg IV thiamine (Pabrinex)

Step 3: Benzodiazepines (pharmacological backbone)

Fixed-schedule (front-loading) protocol, Diazepam:

• Day 1: 20 mg QID (or higher based on CIWA-Ar)
• Reduce by 20–25% per day
• Taper over 5–10 days

Symptom-triggered protocol: CIWA-Ar ≥8 → give diazepam 10–20 mg; reassess every 1–2 hours.

Step 4: Adjuncts

• Thiamine: Continue oral for 2 weeks post-detox
• Multivitamins: Folate, B12
• Clonidine: Autonomic symptoms (adjunct, not primary)
• Beta-blockers (propranolol): HR/BP; no anticonvulsant effect, do NOT use alone
• Carbamazepine: Alternative anticonvulsant; preferred in outpatient mild-moderate withdrawal; not standard for DTs
• Haloperidol: For psychotic symptoms in DTs; NEVER as sole agent (no anticonvulsant effect)
• Magnesium: If hypomagnesemia

Managing DTs:

• ICU/HDU
• IV diazepam: boluses of 5–10 mg every 5–15 minutes until calm; then infusion or PO
• IV lorazepam alternative
• Monitor: airway, BP, temperature, glucose
• Treat precipitating factors: infection, head injury

2.8 Relapse Prevention (Pharmacotherapy)

Psychosocial treatments:

• Motivational Enhancement Therapy (MET), 2–4 sessions
• Cognitive Behavioural Therapy (CBT), relapse prevention focused
• 12-Step Facilitation (Alcoholics Anonymous)
• Behavioural Couples Therapy
• Community Reinforcement Approach (CRA)

2.9 Wernicke-Korsakoff Syndrome

Thiamine deficiency in alcohol use disorder, the pathophysiology:

• Inadequate dietary intake
• Malabsorption
• Increased metabolic demand
• Impaired hepatic storage

Wernicke's Encephalopathy (acute):

Korsakoff's Syndrome (chronic amnestic):

• Anterograde amnesia (new learning severely impaired) > retrograde amnesia
• Confabulation (unconscious fabrication to fill memory gaps)
• Relative preservation of other cognitive functions
• Insight usually absent
• Neurologically: dorsomedial thalamus + mammillary body atrophy
• Outcome: ~25% significant recovery, ~50% partial, ~25% minimal improvement

2.10 Alcoholic Hallucinosis

2.11 Pathological Intoxication (Alcohol Idiosyncratic Intoxication)

• Extreme behavioral change (aggression, violence) after small amounts of alcohol
• Disproportionate to amount consumed
• Amnesia for the episode common
• Rare; uncertain whether distinct entity
• Mechanism: possibly related to temporal lobe sensitivity, epileptic disinhibition
• DSM-5: absorbed into "other specified alcohol-related disorder"

2.12 Fetal Alcohol Spectrum Disorders (FASD)

No safe level of alcohol in pregnancy.

FAS Facial Features (facial dysmorphology triad):

• Smooth philtrum
• Thin vermilion border of upper lip
• Short palpebral fissures

CNS effects:

• Microcephaly, intellectual disability
• ADHD, learning disabilities
• Behavioral problems
• Impaired executive function

SECTION 3: OPIOID USE DISORDERS

3.1 Epidemiology

• Global: ~62 million people use opioids non-medically (UNODC 2022)
• India: ~2.26 million heroin users (UNODC); significant rise in pharmaceutical opioid misuse
• Biggest contributor to overdose deaths globally
• India NDPS Act: heroin Schedule I, pharmaceutical opioids Schedule II (regulatory complexity)

3.2 Pharmacology

Opioid receptors (all are GPCRs, Gi/o coupled → ↓cAMP, K+ channel open, Ca2+ channel closed → neuronal inhibition):

Endogenous ligands:

• Beta-endorphin → MOR
• Met/Leu-enkephalin → DOR
• Dynorphin → KOR
• Nociceptin → NOP

3.3 Heroin

• Diacetylmorphine
• More lipophilic than morphine → crosses BBB faster → intense rush
• Rapidly hydrolyzed to 6-monoacetylmorphine → morphine
• Route: IV (most bioavailable), smoked ("chasing the dragon"), intranasal

3.4 Opioid Intoxication

3.5 Opioid Withdrawal

Timeline (heroin):

• Short-acting opioids (heroin): begins 6–24 hours post-dose; peaks 36–72 hours; resolves 5–7 days
• Long-acting opioids (methadone): begins 24–48 hours; peaks 3–5 days; resolves 2–3 weeks

COWS (Clinical Opiate Withdrawal Scale), 11 items:

Score interpretation:

• 5–12: Mild
• 13–24: Moderate
• 25–36: Moderately severe
• >36: Severe

Mnemonic for opioid withdrawal signs: "DAMP COIL"

• Diarrhea
• Anxiety
• Mydriasis (dilated pupils)
• Piloerection
• Cramps/muscle aches
• Only not life-threatening (except in neonates/pregnancy)
• Insomnia
• Lacrimation/rhinorrhea

3.6 Opioid Substitution Therapy (OST)

Rationale: Replace illicit, short-acting opioid with long-acting, orally administered, medically supervised opioid → stabilize, reduce craving, reduce needle use, reduce crime, reduce mortality.

Buprenorphine/Naloxone (Suboxone):

• Naloxone is bioavailable only IV, not sublingually
• If injected IV (diverted): naloxone becomes active → precipitates withdrawal → deters IV misuse
• Sublingual: only buprenorphine effect

3.7 Naloxone for Overdose Reversal

3.8 Neonatal Opioid Withdrawal Syndrome (NOWS) / Neonatal Abstinence Syndrome (NAS)

When: Infant born to opioid-dependent mother (prescribed or illicit); onset 24–72 hours for heroin, up to 5–7 days for methadone.

Finnegan Neonatal Abstinence Scoring System:

Signs scored: high-pitched cry, sleep <3 hours, sleep <2 hours, hyperactive Moro reflex, tremors, muscle tone increased, excoriation, frequent yawning, mottling, fever, sweating, nasal stuffiness, sneezing, nasal flaring, respiratory rate >60, feeding problems, regurgitation, vomiting, loose stools, watery stools.

Score ≥8 on two occasions → pharmacological treatment:

• First-line: Oral morphine or methadone
• Adjunct: Phenobarbital for seizures
• Breastfeeding (if not HIV+, no drug use except OST): encouraged; reduces NOWS severity

SECTION 4: CANNABIS USE DISORDERS

4.1 The Endocannabinoid System

Delta-9-THC (primary psychoactive constituent):

• Partial CB1/CB2 agonist
• Highly lipophilic → crosses BBB rapidly
• Metabolized to active metabolite 11-OH-THC
• Stored in fat → prolonged urinary detection (2–4 weeks in heavy users)

CBD (cannabidiol):

• Non-psychoactive
• CB1 negative allosteric modulator; also 5-HT1A agonist, TRPV1 agonist
• Anticonvulsant, anxiolytic properties
• May attenuate THC-induced psychosis risk

4.2 Acute Intoxication

• Euphoria, relaxation, altered perception of time, increased appetite ("munchies")
• Impaired short-term memory, concentration
• Tachycardia, conjunctival injection, dry mouth
• Anxiety, panic (especially naive users or high-THC products)
• Perceptual distortions (not true hallucinations usually)

4.3 Cannabis Use Disorder

• ~9% of users develop dependence (compare: tobacco 32%, heroin 23%, cocaine 17%)
• Higher risk with: early onset use, daily/near-daily use, high-potency products, co-occurring anxiety/depression
• DSM-5 criteria: 2+ of 11 within 12 months
• No pharmacologically validated treatment; psychosocial (CBT, MI, CM) primary

Cannabis Withdrawal Syndrome (ICD-11, DSM-5 recognized):

Onset 24–72 hours; peaks 2–6 days; resolves 1–2 weeks

Symptoms: Irritability/anger/aggression, anxiety, sleep disturbance, appetite decrease, restlessness, depressed mood, GI disturbance, somatic discomfort (headache, sweats, chills)

4.4 Amotivational Syndrome

• Chronic cannabis use → apathy, reduced goal-directed activity, decreased motivation, flat affect
• Mechanism: chronic CB1 agonism → downregulation in prefrontal cortex → reduced dopaminergic drive
• Controversial as distinct entity vs intoxication state vs comorbid depression
• Partially reversible with sustained abstinence

4.5 Cannabis-Induced Psychosis

The THC:CBD ratio matters, high THC/low CBD products (modern skunk) have higher psychotomimetic risk than balanced products.

4.6 Synthetic Cannabinoids ("Spice," "K2," "Mambas")

• Full CB1 agonists (vs THC partial) → more potent, more toxic
• Clinical features more severe: psychosis, seizures, AKI, cardiovascular events, death
• No specific antidote; supportive management
• Not detected on standard urine drug screens

SECTION 5: TOBACCO USE DISORDER

5.1 Nicotine Pharmacology

5.2 Fagerstrom Test for Nicotine Dependence (FTND)

6 questions (0–10 score):

Score: 0–3 low; 4–6 moderate; 7–10 high dependence

5.3 Treatment of Nicotine Dependence

5 A's framework: Ask → Advise → Assess → Assist → Arrange

5 R's for unmotivated patients: Relevance → Risks → Rewards → Roadblocks → Repetition

SECTION 6: STIMULANT USE DISORDERS

6.1 Cocaine

Pharmacology:

• Blocks reuptake transporters for DA, NE, 5-HT (primarily DA reuptake inhibitor in striatum)
• Also: local anesthetic (Na channel blockade)
• Routes: intranasal ("snorting"), IV, smoked as crack cocaine

Crack vs powder cocaine:

Cocaine intoxication:

• Euphoria, grandiosity, increased energy, decreased appetite
• Tachycardia, hypertension, dilated pupils, diaphoresis
• With high doses: paranoia, perceptual disturbances

Cocaine "crash" (withdrawal):

• Dysphoria, fatigue, hypersomnia, hyperphagia, depression, craving
• No physiological withdrawal per se; psychological craving intense
• Phase: post-acute withdrawal → "extinction" phase (month-long craving cycles triggered by cues)

Cocaine-induced psychosis:

• Paranoid delusions, tactile hallucinations (formication, "coke bugs")
• Auditory hallucinations
• Clear sensorium usually maintained
• Typically resolves within days to weeks of abstinence

Medical complications of cocaine:

• Cardiovascular: MI (even in young users), arrhythmia, aortic dissection, cardiomyopathy
• Pulmonary: "crack lung", acute pneumonitis
• Neurological: stroke, seizure
• Nasal: septum perforation, rhinitis, anosmia

6.2 Amphetamines and Methamphetamine

Mechanism:

• Reverses DAT, NET, SERT (releases stored monoamines), not just reuptake blockade
• Net effect: massive increase in synaptic DA, NE, 5-HT

Methamphetamine ("crystal meth"):

• More potent and longer-acting than amphetamine
• Routes: smoked, IV, intranasal
• Neurotoxicity: damages DA and 5-HT terminals with chronic use → Parkinsonism, cognitive decline
• "Meth mouth": severe dental decay from xerostomia, bruxism, acidic environment

MDMA (3,4-methylenedioxymethamphetamine / Ecstasy):

• Releases 5-HT (primary) > DA; also oxytocin release
• Acute: empathogen, euphoria, increased sociability
• Neurotoxic to serotonergic neurons with repeated use
• Hyperthermia (dangerous; serotonin syndrome risk)
• Hyponatremia (drinking excess water while dancing)

SECTION 7: SEDATIVE-HYPNOTIC USE DISORDERS

7.1 Benzodiazepine Pharmacology

• Positive allosteric modulators of GABA-A receptor (chloride channel)
• Increase frequency of Cl− channel opening (not duration, that's barbiturates)
• Binding site distinct from alcohol/barbiturate sites but all converge on GABA-A

Clinical uses: Anxiety, insomnia, seizures, acute alcohol withdrawal, muscle relaxation, pre-anaesthetic

7.2 Benzodiazepine Dependence

Risk factors: Longer duration of use (>4–6 weeks at therapeutic doses), higher dose, short-acting agents, prior dependence history, anxiety disorders, elderly.

Withdrawal: Similar to alcohol withdrawal (GABA-related); potentially life-threatening

Withdrawal timeline:

• Short-acting (lorazepam, alprazolam, triazolam): 24–48 hours onset; peaks 2–4 days
• Long-acting (diazepam, clonazepam, chlordiazepoxide): 5–7 days onset; peaks 2 weeks

Withdrawal symptoms:

• Anxiety, insomnia, tremor, diaphoresis, tachycardia, hypertension
• Perceptual hypersensitivity (sensory, light, sound)
• Seizures (particularly with abrupt cessation of short-acting benzos)
• Delirium (rare but serious)

Management of BZD dependence:

1. Switch to long-acting BZD (diazepam equivalent)
2. Slow taper, typically over weeks to months (NOT the rapid 5–10 day protocol of alcohol)
3. Typical rate: 10% per week; slower as dose decreases
4. Adjuncts: CBT (particularly for anxiety), sleep hygiene

7.3 Z-Drugs (Non-Benzodiazepine Hypnotics)

• Zolpidem, zaleplon, zopiclone (eszopiclone)
• Act on BZD receptor but with more selectivity for α1 subunit (sedation) vs α2 (anxiolysis)
• Lower dependence potential than BZDs (theoretical; clinical evidence mixed)
• Same withdrawal profile at high doses/long duration
• Unusual sleep behaviors: sleep-walking, sleep-eating, sleep-driving

7.4 GHB (Gamma-Hydroxybutyrate)

• Endogenous GABA precursor + GHB receptor agonist at low doses; GABA-B agonist at high doses
• Medical use: narcolepsy (sodium oxybate), alcohol withdrawal (in some countries)
• Abuse: "club drug," recreational use, "date rape drug" (rapid sedation/amnesia)
• Narrow therapeutic window; overdose: loss of consciousness, respiratory depression, coma
• Withdrawal: alcohol-like withdrawal syndrome; potentially severe

SECTION 8: NOVEL AND EMERGING SUBSTANCES

8.1 Kratom (Mitragyna speciosa)

• Tropical plant (Southeast Asia); leaves chewed or brewed
• Active alkaloids: mitragynine and 7-hydroxymitragynine
• Mechanism: partial MOR agonist at high doses; stimulant at low doses
• Uses: self-treatment of opioid withdrawal, pain, fatigue
• Dependence: opioid-like withdrawal syndrome
• Pharmacokinetics: half-life ~9 hours
• Legal status varies; increasing global use

8.2 Synthetic Cathinones ("Bath Salts")

• Structural analogs of cathinone (khat plant alkaloid)
• Examples: mephedrone, MDPV, alpha-PVP
• Mechanism: monoamine releasing/reuptake blocking (DA > NE > 5-HT)
• Clinical features: stimulant effects + psychosis; "excited delirium"
• High lethality potential: hyperthermia, rhabdomyolysis, cardiovascular collapse
• Not detected on standard drug screens

8.3 Novel Psychoactive Substances (NPS)

• Designed to mimic effects of controlled substances while remaining technically legal ("designer drugs")
• Categories: synthetic cannabinoids, synthetic cathinones, novel phenethylamines (NBOMe series), novel opioids (fentanyl analogs), dissociatives (novel ketamine analogs)
• Surveillance challenge: new compounds emerge faster than they can be scheduled
• India: Amendment to NDPS Act attempts to include analog compounds

8.4 Inhalants

• Toluene (glue), gasoline, nitrous oxide, amyl/butyl nitrite ("poppers")
• Particularly prevalent in adolescents, homeless populations, India (Pidilite/Fevicol sniffing)
• Mechanism: CNS depression (general anesthetic-like); toluene: GABA-A + NMDA effects
• Toxic: "sudden sniffing death" (ventricular fibrillation); cerebellar atrophy; dementia; white matter damage
• No pharmacological treatment; psychosocial focus

SECTION 9: MOTIVATIONAL INTERVIEWING

9.1 Definition and Spirit

MI is a collaborative, person-centered form of guiding to elicit and strengthen motivation for change.

MI Spirit (PACE):

• Partnership, collaborative, not expert-to-client
• Acceptance, absolute worth, accurate empathy, autonomy support, affirmation
• Compassion, active promotion of client's welfare
• Evocation, drawing out client's own motivation and wisdom

9.2 Four Processes of MI

1. Engaging, establishing a working relationship
2. Focusing, developing and maintaining a specific direction
3. Evoking, eliciting motivation for change
4. Planning, developing commitment and plan

9.3 Core Skills: OARS

9.4 Change Talk and Sustain Talk

Change talk (DARN CAT):

• Desire ("I want to...")
• Ability ("I could...")
• Reason ("Because...")
• Need ("I need to...")
• Commitment ("I will...")
• Activation ("I'm ready to...")
• Taking steps ("I've already...")

Sustain talk: Arguments for the status quo ("But I enjoy it...", "I'm not that bad...")

Discord: Defensiveness, argument, changing subject, respond with reflection, not argument

9.5 Ambivalence and Decisional Balance

A central MI concept: ambivalence (simultaneously wanting and not wanting to change) is normal, not pathological. The task is to explore ambivalence rather than confront or argue with it.

Decisional balance: Explore costs and benefits of both change and status quo.

SECTION 10: STAGES OF CHANGE (TRANSTHEORETICAL MODEL)

10.1 Prochaska & DiClemente Model

SECTION 11: BRIEF INTERVENTIONS

11.1 FRAMES (Components of Effective Brief Intervention)

• Feedback, personalized feedback on risk/harm
• Responsibility, emphasize personal responsibility for change
• Advice, clear advice to change
• Menu, range of options for change
• Empathy, warm, empathic counseling style
• Self-efficacy, build belief in ability to change

11.2 Screening Tools

AUDIT (Alcohol Use Disorders Identification Test):

• 10 items; covers frequency, quantity, dependence features, consequences
• Score 0–40
• Threshold: ≥8 hazardous/harmful use; ≥15 likely dependence
• Developed by WHO; validated cross-culturally
• AUDIT-C (3 items): brief screen; score ≥4 men, ≥3 women = positive

CAGE (4 questions):

• Cut down, ever felt you should cut down?
• Annoyed, have people annoyed you by criticizing your drinking?
• Guilty, ever felt guilty about drinking?
• Eye opener, ever had a drink first thing in the morning (eye opener)?
• Score ≥2: clinically significant; sensitivity ~74%, specificity ~91%

MAST (Michigan Alcohol Screening Test):

• 25-item questionnaire; score >5 indicates alcoholism
• Brief MAST (13 items) also available

DAST (Drug Abuse Screening Test):

• 28-item (or 10-item) tool for non-alcohol substances
• Score ≥6 = substance abuse

SECTION 12: DUAL DIAGNOSIS

12.1 Epidemiology

• ~50% of those with severe mental illness have a lifetime SUD
• ~50% of those with SUD have a lifetime psychiatric disorder
• Most common combinations:
• Alcohol + Depression/Anxiety
• Stimulants + Psychosis/Bipolar
• Cannabis + Psychosis/Anxiety
• Opioids + Depression/PTSD

12.2 Pathways Linking SUD and Mental Illness

12.3 Management Principles

Integrated treatment is superior to sequential or parallel approaches:

• Address both disorders simultaneously in same setting
• Same team, shared conceptual model
• Stage-wise approach (engagement → persuasion → active treatment → relapse prevention)
• Modified MI for dual diagnosis: accept low motivation early; build engagement first

Sequential approach (outdated): Treat one before the other, poor outcomes

Medication principles:

• Use formulations with lower abuse potential where possible
• Monitor for interactions (e.g., antidepressants + alcohol)
• SSRIs: first-line for depression/anxiety in SUD; may also reduce drinking
• Naltrexone: avoid if on opioids; helpful for alcohol in depression comorbidity
• Antipsychotics: avoid olanzapine/clozapine in stimulant users (metabolic risk compounded)

SECTION 13: INDIAN CONTEXT

13.1 NDPS Act (Narcotic Drugs and Psychotropic Substances Act, 1985)

Key provisions:

Small quantities under NDPS:

• Opium: 25 grams
• Heroin: 5 grams
• Cocaine: 2 grams
• Cannabis (charas): 100 grams; ganja: 1 kg
• Amphetamine: 2 grams

13.2 De-addiction Infrastructure in India

13.3 Drug Trends in India

• Alcohol: most prevalent; rising female use
• Pharmaceutical opioids: codeine-containing cough syrups, tramadol, buprenorphine misuse
• Heroin: Punjab, Rajasthan, Northeast India (Golden Crescent and Golden Triangle routes)
• Cannabis: widespread; increasing synthetic cannabis reports
• Stimulants: amphetamine use rising in trucking industry
• Tobacco: dual use (smoked + smokeless)

SECTION 14: SPECIAL TOPICS

14.1 Pharmacogenomics Relevant to Addiction

14.2 Neurobiological Circuits in Addiction

Three-stage cycle (Koob & Volkow):

14.3 Reward Deficiency Syndrome

Concept: individuals with blunted dopaminergic reward systems (genetic, developmental) are at higher risk for addiction (and other compulsive behaviors). Basis for DA-based pharmacological strategies.

14.4 Process Addictions

• Gambling disorder (only non-substance addiction in DSM-5 SUD chapter)
• Gaming disorder (ICD-11: addictive behaviors section)
• Internet gaming, social media, pornography (under research)
• Same neurobiological circuits as substance use

SECTION 15: HIGH-YIELD DRUG FACTS TABLE

Model Answers

HOW TO USE THIS FILE

Each answer is structured for a 10-mark long-answer question. Recommended time: 15–18 minutes per question. Target: 1 mark per ~1.5 minutes of reading. Write introductory definition, classification, body, a table, and a conclusion.

Q1. Discuss the management of alcohol withdrawal syndrome. [10 marks]

Answer:

Definition

Alcohol withdrawal syndrome (AWS) is a clinically significant constellation of symptoms occurring when alcohol-dependent individuals abruptly stop or markedly reduce intake. It results from removal of alcohol's chronic positive allosteric modulation of GABA-A receptors and inhibition of NMDA glutamate receptors, leading to CNS hyperexcitability.

Clinical Spectrum and Timeline

Swipe to compare →

Assessment Tools

CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, revised):

• 10 items: nausea, tremor, paroxysmal sweats, anxiety, agitation, tactile/auditory/visual disturbances, headache, orientation
• Score <8: mild; 8–15: moderate; >15: severe; >20: ICU-level care

Management Algorithm

Step 1, Immediate assessment

• Full clinical examination, vital signs
• Blood tests: glucose, electrolytes (Na, K, Mg, phosphate), LFTs, CBC, coagulation, toxicology screen
• Identify concurrent medical illness (infection, head injury, liver disease)

Step 2, Thiamine (mandatory before glucose)

• 100–200 mg IV/IM thiamine BEFORE any IV glucose
• Rationale: Prevents precipitation of Wernicke's encephalopathy in thiamine-depleted state
• High-risk patients (malnourished, heavy drinkers): 500 mg IV thiamine (Pabrinex)

Step 3, Pharmacological management

Benzodiazepines (cornerstone of treatment):

Dosing strategies:

• Fixed-schedule with CIWA-Ar monitoring: Diazepam 20 mg QID Day 1 → taper 20% per day over 5–7 days
• Symptom-triggered (preferred where feasible): CIWA-Ar ≥8 → give BZD; reassess every 1–2 hours; uses significantly less benzodiazepine

Step 4, Specific complications

Withdrawal seizures:

• IV diazepam 10–20 mg for active seizure
• If seizures recur: IV lorazepam or phenytoin loading
• Carbamazepine: alternative outpatient anticonvulsant for mild withdrawal

Delirium tremens:

• ICU/HDU monitoring
• IV diazepam titrated to calm patient (may need large doses: 100–200 mg in 24 hours)
• Correct hypoglycemia, hypomagnesemia, electrolyte imbalances
• Antipyretics for hyperthermia
• Haloperidol ONLY as adjunct for psychotic symptoms, NEVER as sole treatment (no anticonvulsant effect)
• Mortality: <1% with treatment vs 15–35% untreated

Step 5, Nutritional and general support

• Oral thiamine continue 2 weeks post-detox
• Multivitamins: folate, B12, B6
• Oral/IV hydration
• High-calorie diet

Step 6, Relapse prevention (post-detox)

• Disulfiram 250–500 mg/day (supervised)
• Naltrexone 50 mg/day
• Acamprosate 666 mg TID
• Psychosocial: CBT, MI, AA/NA, family therapy

Prognosis

Without intervention: 3–5% risk of DTs; ~3% seizure risk; significant recidivism. With structured management: DTs mortality <1%; long-term sobriety improved with combined pharmacotherapy + psychosocial treatment.

Q2. Compare and contrast disulfiram, naltrexone, and acamprosate in the management of alcohol dependence. [10 marks]

Answer:

Introduction

Pharmacological relapse prevention is a key component of AUD management after successful detoxification. Three agents, disulfiram, naltrexone, and acamprosate, have the strongest evidence base and are approved by major regulatory agencies. They work through distinct mechanisms and are suited to different clinical profiles.

Mechanisms of Action

Head-to-Head Comparison

Disulfiram-Ethanol Reaction (DER)

When alcohol is consumed, acetaldehyde accumulates:

• Flushing, pulsating headache, nausea, vomiting
• Tachycardia, palpitations, hypotension
• Dyspnoea, sweating
• Severe cases: cardiovascular collapse, unconsciousness
• Treatment: supportive; IV fluids, antihistamine (H1 + H2), vitamin C; vasopressors if needed

Practical Prescribing Decision Framework

Evidence Summary

• COMBINE trial: Naltrexone reduced % heavy drinking days; acamprosate not superior to placebo in US population; combined not better than naltrexone alone
• European data: Acamprosate strongly effective in post-detox abstinence in European populations
• Project MATCH: MI, CBT, and 12-step similarly effective psychosocially
• Baclofen (additional): GABA-B agonist; emerging evidence particularly for anxious patients; not yet first-line

Q3. Discuss opioid substitution therapy (OST) in the management of opioid use disorder. [10 marks]

Answer:

Definition

Opioid substitution therapy (OST) is the provision of a prescribed, pharmacologically active opioid (or partial agonist) in a supervised, controlled clinical setting to reduce illicit opioid use, harm associated with injection, and mortality. It is the evidence-based standard of care for opioid dependence.

Rationale

• Illicit opioid use: uncontrolled dose, contaminants, needle sharing (BBV transmission), crime
• OST stabilizes the neurobiological state, reduces craving, prevents withdrawal
• Harm reduction: HIV, Hepatitis B/C prevention
• Social reintegration: employment, family functioning
• Reduces mortality by 50% or more

WHO Position

OST (methadone and buprenorphine) is on the WHO Essential Medicines List. Declared a "highly cost-effective" intervention. Recommended as first-line for moderate-severe OUD.

Agents Used in OST

1. Methadone

2. Buprenorphine (Subutex) and Buprenorphine/Naloxone (Suboxone)

Methadone vs Buprenorphine Comparison

Induction Protocol (Buprenorphine)

1. Patient education: must be in moderate withdrawal (COWS ≥8–12)
2. Day 1: 4 mg SL → observe 1–2 hours → if tolerated, 4 mg more → total 8 mg Day 1
3. Day 2–3: titrate to 12–16 mg
4. Week 2–4: target maintenance dose (16–24 mg usual)
5. Supervised dispensing initially; take-home doses after 3 months stable

Adjuncts and Psychosocial Components

OST is NOT medication alone:

• Contingency management (CM): positive reinforcement for drug-free urines
• CBT: relapse prevention, coping skills
• Motivational Enhancement Therapy
• Case management: housing, employment, legal
• Family therapy where appropriate
• Mutual aid: NA, SMART Recovery

Duration

OST is long-term treatment, minimum 12–24 months, often indefinitely. Premature cessation → high relapse rate. Slow supervised taper (if desired): reduce by 2–4 mg/month.

Indian Context

• National Drug Dependence Treatment Centre (NDDTC), PG exams: OST program
• Drug Treatment Centres (DTCs): government-run buprenorphine dispensation
• NDPS Act Section 71: judicial powers to mandate treatment
• Challenges: stigma toward OST ("replacing one drug with another"), limited qualified providers, strict regulations

Outcomes

• ~50% reduction in illicit opioid use
• HIV incidence reduction ~54%
• Overdose mortality reduction: 50–70%
• Retention in treatment at 12 months: methadone ~60–65%; buprenorphine ~55–60%
• Superior retention with higher doses (>60 mg methadone; >16 mg buprenorphine)

Q4. Discuss cannabis and psychosis: is the relationship causal? [10 marks]

Answer:

Introduction

The relationship between cannabis use and psychotic disorders has been debated for decades. Accumulating epidemiological, experimental, and genetic evidence now supports a component cause model: cannabis is neither a necessary nor sufficient cause of psychosis, but it reliably increases risk, the relationship is causal.

Epidemiological Evidence

Bradford Hill Criteria for causality:

Mechanisms

Dopaminergic pathway:

• THC → CB1 stimulation in VTA → increased DA synthesis and release in striatum
• Striatal hyperdopaminergia = the final common pathway of psychosis
• PET studies: THC increases striatal DA release in healthy volunteers

Prefrontal cortex:

• CB1 receptors in PFC → THC impairs PFC function → reduced inhibitory control over subcortical DA
• Mirrors disinhibition hypothesis of schizophrenia

Glutamate-DA interaction:

• THC impairs NMDA receptor function → similar to ketamine model of psychosis

THC:CBD ratio:

• CBD is a CB1 negative allosteric modulator
• High-CBD products associated with lower psychotomimetic risk
• Modern skunk (high THC/low CBD) → highest risk

Cannabis-Induced Psychosis vs Primary Psychosis

Moderating Factors

• Genetic vulnerability: COMT Val158Met polymorphism, Val/Val carriers more vulnerable to cannabis-induced psychosis
• Age of onset: Adolescent use carries greater risk (neurodevelopmental sensitivity)
• Frequency and duration: Daily/near-daily use, long duration
• Product potency: High-THC products (>10% THC)
• Pre-existing subclinical psychosis: Cannabis precipitates in those already on the psychosis continuum

Clinical Implications

• Substance use history: mandatory in any psychosis assessment
• Drug screen: THC in urine, blood
• Management:
• Psychoeducation: evidence-based information about risk
• Motivational interviewing for cessation
• Antipsychotics for acute cannabis-induced psychosis
• Monitor: if psychosis persists >1 month after abstinence → reassess diagnosis

Q5. Describe motivational interviewing in substance use disorders. [10 marks]

Answer:

Definition

Motivational Interviewing (MI) is an evidence-based, person-centered counseling approach developed by William Miller and Stephen Rollnick (1991). It is defined as "a collaborative, goal-oriented style of communication with particular attention to the language of change, designed to strengthen personal motivation and commitment to a specific goal by eliciting and exploring the person's own reasons for change within an atmosphere of acceptance and compassion."

Theoretical Foundation

MI emerged from the Transtheoretical Model (Prochaska & DiClemente) and Carl Rogers' person-centered therapy. The central insight: people change when they articulate their own reasons for change, external pressure is counterproductive.

Ambivalence: MI views ambivalence as a normal state, not resistance or denial. It is the simultaneous desire to change and not to change. MI's role is to resolve ambivalence in the direction of change.

MI Spirit (PACE)

Four Processes

Core Skills: OARS

Change Talk: DARN-CAT

Change talk = client speech that favors change.

Preparatory change talk (DARN):

• Desire: "I want to cut back"
• Ability: "I could stop if I wanted to"
• Reason: "My liver results scared me"
• Need: "I need to do something"

Mobilizing change talk (CAT):

• Commitment: "I will try to reduce"
• Activation: "I'm ready to make a change"
• Taking steps: "I've already thrown out the bottles"

Sustain talk: Client arguing for status quo, reflect, don't argue. "Rolling with resistance" = working with not against.

Evoking Change Talk: Strategies

1. Decisional balance: "What are the good things about your drinking? What are the less good things?"
2. Importance and confidence rulers: "On a scale of 0–10, how important is it to you to change? Why not a lower number?"
3. Looking forward/back: "How was your life before alcohol became a problem? How do you see it in 5 years if nothing changes?"
4. Exploring values: "What matters most to you? How does your drinking fit with that?"

Evidence Base

Application in Different Settings

• Brief intervention (5–15 min): FRAMES model; AUDIT/CAGE → feedback → brief MI
• Motivational Enhancement Therapy (MET): 2–4 structured sessions; adapted from MI
• Dual diagnosis: Adapted MI, longer engagement phase; address mental illness first; no confrontation of denial

Q6. Discuss the AUDIT and CAGE screening tools for alcohol use disorders. [10 marks]

Answer:

Introduction

Screening for harmful and hazardous alcohol use is a critical component of clinical practice. Two tools dominate: AUDIT (Alcohol Use Disorders Identification Test), developed by the WHO for cross-cultural application, and CAGE, a 4-item clinical screening instrument. Both detect problematic drinking but have different characteristics, validity profiles, and appropriate clinical settings.

AUDIT (Alcohol Use Disorders Identification Test)

Development: WHO collaborative project (Babor et al., 1989). Validated in multiple countries including India.

Structure, 10 items across 3 domains:

Scoring:

• Each item: 0–4 (except Q9 and Q10: 0, 2, or 4 only)
• Total: 0–40

Threshold for positive screen: ≥8 in most settings; some studies use ≥7 for greater sensitivity.

AUDIT-C (3-item brief version):

• Items 1–3 only (frequency, quantity, frequency of binge)
• Threshold: ≥4 (men), ≥3 (women)
• Sensitivity 73–91% for hazardous use
• Suitable for very brief screening (30 seconds)

Psychometric properties:

• Sensitivity ~57–97%, Specificity ~78–96% (varies by threshold and population)
• Validated in Indian clinical settings (Ebrahim et al.)

CAGE Questionnaire

Development: Ewing (1984). 4-item mnemonic tool.

Questions:

Scoring: Each "yes" = 1 point (0–4)

Psychometric properties:

• Sensitivity: ~74–85%; Specificity: ~79–91% for alcohol dependence
• Best validated for detecting dependence (not hazardous use)

AUDIT vs CAGE: Comparison

Other Screening Tools

Q7. Discuss Wernicke-Korsakoff syndrome in the context of alcohol use disorder. [10 marks]

Answer:

Introduction

Wernicke-Korsakoff syndrome (WKS) is a neuropsychiatric complication of thiamine (Vitamin B1) deficiency, most commonly seen in the context of alcohol use disorder. It represents a clinical continuum: Wernicke's encephalopathy (acute, reversible if treated promptly) → Korsakoff's syndrome (chronic amnestic, largely irreversible).

Thiamine Deficiency in AUD: Pathophysiology

Thiamine function: Cofactor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, transketolase → ATP production in Krebs cycle → CNS most vulnerable to energy failure.

Wernicke's Encephalopathy (Acute)

Classic triad:

1. Ophthalmoplegia, lateral rectus palsy (most common), nystagmus, conjugate gaze palsy
2. Ataxia, cerebellar; wide-based gait; lower limb > upper limb
3. Confusion / encephalopathy, global confusion, disorientation

Pathology:

• Petechial hemorrhages, edema, astrocyte proliferation
• Location: mammillary bodies (most specific), dorsomedial thalamus, periaqueductal grey, cerebellar vermis

MRI findings:

• Hyperintensity on FLAIR/T2W in mammillary bodies, thalamus, periaqueductal grey
• Mammillary body atrophy (classic)

Treatment (emergency):

Critical rule: Thiamine BEFORE IV glucose in ANY alcohol-dependent patient, glucose infusion without thiamine can precipitate acute Wernicke's by depleting remaining thiamine reserves.

Korsakoff's Syndrome (Chronic)

Pathological substrate: Dorsomedial thalamic nucleus atrophy; mammillary body atrophy; frontal lobe involvement.

Clinical features:

Prognosis:

• ~25% significant improvement with abstinence + thiamine
• ~50% partial improvement
• ~25% minimal improvement
• Time to recovery: months to years
• Predictors of poor outcome: long duration before treatment, severe malnutrition, continued alcohol use

Korsakoff's vs Other Dementias:

Q8. Describe the clinical features and management of delirium tremens. [10 marks]

Answer:

Definition

Delirium tremens (DTs) is the most severe manifestation of alcohol withdrawal syndrome, characterized by global confusion (delirium), severe autonomic hyperactivity, and perceptual disturbances. It represents a medical emergency with mortality of 15–35% if untreated, reduced to <1% with appropriate management.

Epidemiology and Risk Factors

Occurs in approximately 3–5% of hospitalized alcohol withdrawal patients.

Risk factors for DTs:

Pathophysiology

Chronic alcohol ingestion:

• Downregulates GABA-A receptors (tolerance to CNS depression)
• Upregulates NMDA glutamate receptors

Alcohol withdrawal:

• Reduced GABAergic tone → excitatory dominance
• Unmasked NMDA hyperactivity → neuronal hyperexcitability
• Noradrenergic hyperactivity (locus coeruleus) → autonomic storm
• Dopaminergic excess → hallucinations

Clinical Features

Onset: 48–72 hours after last drink (can extend to 5–7 days)

Duration: Typically 3–5 days if treated; can persist

DTs vs Alcoholic Hallucinosis Comparison

Management

Step 1, Immediate stabilization

• ICU or HDU admission
• IV access × 2
• Continuous monitoring: HR, BP, temperature, oxygen saturation, glucose
• Airway management if required

Step 2, Thiamine first

• 200–500 mg IV thiamine (before any glucose)
• Continue 100 mg TID for 2–3 days

Step 3, Benzodiazepines (primary pharmacotherapy)

Step 4, Adjuncts

Step 5, Treat precipitants

• Blood cultures and broad-spectrum antibiotics if infection suspected
• CT head if focal neurology or head injury
• Correct hyponatremia, hypoglycemia, hypophosphatemia

Step 6, Monitoring and endpoints

• CIWA-Ar every 4–8 hours; target <8 before stepping down
• Watch for: aspiration pneumonia, cardiovascular events, hyperthermia complications
• Transition to oral regimen when stable

Prognosis

With treatment: mortality <1%. Predictors of poor outcome: concurrent liver failure, severe hyperthermia (>40°C), cardiovascular disease, delayed presentation, pneumonia.

Q9. Describe the Transtheoretical Model of behaviour change and its application in substance use disorders. [10 marks]

Answer:

Introduction

The Transtheoretical Model (TTM), developed by Prochaska and DiClemente (1983), is a model of intentional behavior change that integrates processes and principles of change from across major theories of psychotherapy. It was developed empirically through studying smokers who quit on their own vs with help. Its core concept: behavior change is a process (not an event) moving through predictable stages.

Stages of Change

Processes of Change (10)

Cognitive-experiential processes (earlier stages):

1. Consciousness raising, increasing awareness
2. Dramatic relief, emotional arousal; "it could happen to me"
3. Environmental re-evaluation, impact on others
4. Self-re-evaluation, how substance use conflicts with values
5. Social liberation, awareness of social norms supporting change

Behavioral processes (later stages):

1. Self-liberation, commitment; belief in ability to change
2. Helping relationships, social support
3. Reinforcement management, rewards for behavior change
4. Counterconditioning, alternatives to substance use
5. Stimulus control, avoiding/restructuring cues

Decisional Balance

Central to movement through early stages: weighing pros and cons of both current behavior and proposed change.

Relapse in the TTM

Relapse is not a failure, it is part of the spiral model of change. Studies show:

• Average 3–4 serious quit attempts before sustained cessation (nicotine)
• Relapse is a learning opportunity, each relapse narrows the cycle
• Clinicians should respond non-judgmentally: "What can we learn from this?"

Spiral model: Progress through stages is rarely linear, it is a spiral, with relapses returning to earlier stages but (ideally) at a higher level than before.

Application: Stage-Matched Interventions

Critique of TTM

• Stage boundaries are arbitrary (particularly Contemplation/Preparation)
• Stage classification not reliably predictive of treatment response in all studies
• Discrete stage model may not capture continuous motivational fluctuations
• However: remains the most clinically useful heuristic for matching intervention to readiness

Q10. Discuss brief interventions in alcohol use disorders. [10 marks]

Answer:

Definition

A brief intervention (BI) is a structured but time-limited clinical encounter aimed at individuals whose drinking is risky or harmful (not necessarily dependent), designed to reduce alcohol consumption through motivational feedback and advice. Duration: 5–30 minutes; typically 1–3 sessions.

Rationale

• Population impact: 75–90% of alcohol-related harm occurs in hazardous/harmful users (not dependent)
• These patients are rarely in specialist services, they encounter GPs, ED, primary care
• BI is delivered at the point of identification: opportunistic
• Systematic reviews show: BI reduces drinking by ~4–5 standard drinks/week at 12 months
• Number needed to treat (NNT): ~8 for reduction in hazardous drinking

FRAMES Model

The most cited framework for effective brief interventions:

Screening-Brief Intervention-Referral to Treatment (SBIRT)

The three-tier model:

Evidence Base

Minimal Intervention (5 R's for Unmotivated Patients)

For precontemplators who are not ready to change:

Setting and Delivery

• Primary care: Most evidence; opportunistic; AUDIT screen → BI if score 8–19
• Emergency department: "teachable moment" after alcohol-related injury; modified BI
• Antenatal care: Any alcohol use in pregnancy; non-judgmental BI
• Occupational health: Return-to-work context
• India context: PHC, Jan Aushadhi, de-addiction camps; ANMs and health workers can deliver with training

Limitations

• Efficacy declines at higher AUDIT scores (dependent patients need specialist care)
• In primary care: time pressure; competing priorities; clinician discomfort with alcohol topic
• BI alone insufficient for dependence, gateway to referral, not treatment

Q11. Discuss dual diagnosis: the co-occurrence of substance use and psychiatric disorders. [10 marks]

Answer:

Definition

Dual diagnosis (also: comorbidity, co-occurring disorders) refers to the simultaneous presence of a substance use disorder and one or more psychiatric diagnoses. The term reflects the clinical reality that these conditions frequently co-occur, interact, and complicate each other's management.

Epidemiology

Major studies:

Common pairings:

Pathways

Diagnostic Challenges

• Substance intoxication/withdrawal mimics psychiatric symptoms
• Need 4-week abstinence period ideally to clarify primary vs substance-induced
• In practice: clinical urgency may not allow this
• Temporal relationship crucial: which came first?
• ICD-11/DSM-5: "substance-induced disorder" = causal; "comorbid disorder" = independent

Treatment Approaches

Principles of integrated dual diagnosis treatment:

1. Stage-matched approach: Engagement → persuasion → active treatment → relapse prevention
2. Low threshold for engagement: Accept harm reduction goals initially
3. Assertive community treatment for severe mental illness + SUD
4. Motivational Interviewing adapted for low motivation
5. Residential treatment when severe; abstinence-based milieu
6. Medication principles:
7. Treat both disorders pharmacologically
8. Prefer medications with lower abuse potential
9. SSRIs: first-line for depression/anxiety in AUD
10. Naltrexone: appropriate for AUD even with depression
11. Antipsychotics: clozapine may reduce substance use in schizophrenia

PTSD and SUD

Particularly complex and common:

• PTSD → alcohol/opioids/cannabis as "chemical coping" → SUD
• Both maintain each other: substance withdrawal → PTSD re-experiencing worsens
• Evidence-based treatment: integrated exposure-based CBT (Seeking Safety, COPE)

Q12. Describe neonatal opioid withdrawal syndrome (NOWS). [10 marks]

Answer:

Introduction

Neonatal Opioid Withdrawal Syndrome (NOWS), previously termed Neonatal Abstinence Syndrome (NAS), is a condition in newborns exposed to opioids in utero, manifesting as a constellation of neurological, gastrointestinal, and autonomic signs following delivery. It is a direct consequence of opioid dependence during pregnancy and represents a significant clinical challenge in perinatal medicine.

Prevalence

• USA: dramatic increase; 14 per 1,000 hospital births (2016) vs 1.5 per 1,000 (2000)
• Parallels opioid epidemic
• India: less systematic data; rising with pharmaceutical opioid misuse

Pathophysiology

Opioids cross the placenta freely. Chronic fetal opioid exposure → neuroadaptation (MOR downregulation). At birth, when opioid supply ceases → withdrawal state.

Risk Factors for Severe NOWS

• Tobacco co-exposure (synergistic with opioids)
• SSRI exposure (increases length of stay)
• Long-acting opioids (methadone → prolonged NOWS vs heroin)
• Polypharmacy
• Preterm birth
• Male sex

Clinical Features and Assessment: Finnegan Neonatal Abstinence Scoring System

Onset:

• Short-acting opioids (heroin): 24–72 hours
• Methadone: 48 hours to 5–7 days
• Buprenorphine: 12–48 hours (shorter, milder)

Finnegan categories:

Scoring: Each sign scored 1–3 depending on severity.

• Score ≥8 on two consecutive assessments 4 hours apart → pharmacological treatment indicated

Management

Non-pharmacological (first-line for mild NOWS):

• Skin-to-skin care (kangaroo care)
• Breastfeeding (if mother on OST, not HIV+, no other drug use): decreases NOWS severity and length of stay
• Quiet, low-stimulation environment
• Swaddling, rocking
• Small, frequent feeds (caloric needs increased)

Pharmacological (Finnegan score ≥8 × 2 consecutive):

Weaning: Once stable (Finnegan <8), reduce morphine by 10–20% every 24–48 hours.

Prognosis and Long-Term Outcomes

• NOWS itself: usually resolves within weeks; longer with long-acting opioids
• Long-term: cognitive, behavioral, and developmental concerns
• ADHD, learning difficulties in opioid-exposed children
• Confounded by: socioeconomic factors, maternal mental illness, adverse childhood experiences

Maternal OST and NOWS

• NOWS is expected and manageable in methadone/buprenorphine-exposed neonates
• NOWS from OST is preferred over risks of untreated maternal addiction (preterm birth, fetal growth restriction, overdose)
• Buprenorphine-exposed neonates: shorter, milder NOWS than methadone-exposed (clinical advantage)
• Mothers on OST should NOT be encouraged to taper or stop during pregnancy

Q13. Discuss the NDPS Act provisions relevant to clinical practice. [10 marks]

Answer:

Introduction

The Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985 is India's primary legislation governing narcotic and psychotropic substances. For the psychiatrist, knowledge of the Act is clinically relevant: it shapes how we prescribe controlled substances, advise patients in legal trouble, advocate for treatment over punishment, and access essential medicines.

Background and Purpose

• Enacted to fulfil India's obligations under UN Conventions on Narcotic Drugs (1961), Psychotropic Substances (1971), and Illicit Traffic (1988)
• Replaced Opium Act 1857, Dangerous Drugs Act 1930, Prevention of Illicit Traffic in Narcotic Drugs Act
• Regulates manufacture, sale, purchase, transport, storage, and use of narcotic drugs and psychotropic substances

Key Definitions

Schedules Relevant to Psychiatry

Quantity Thresholds

Penalties:

• Small quantity: rigorous imprisonment up to 1 year + fine, or both
• Intermediate quantity: 1–10 years + fine
• Large quantity: 10–20 years + fine; repeat offence up to 30 years / death in exceptional cases

Provisions Relevant to Treatment

Section 71, Power to establish centres:

"The Government may, in consultation with local authority, establish centres for identification, treatment, education, and rehabilitation of addicts."

This section authorizes the government to refer drug users to treatment instead of the criminal justice pathway. Courts have wide discretion.

Section 76, Probation:

Court may release a convicted person on probation with condition of undergoing treatment for drug dependence.

Section 64-A (Amendment 2001), Immunity from prosecution:

A person who voluntarily seeks treatment for drug dependence is immune from prosecution for offences relating to personal use (small quantity). This is the most important provision for psychiatrists: encourage patients to seek treatment; they are protected.

The 2014 Amendment: Essential Medicines Access

Major reform: removed barriers to prescribing opioids for pain and OST by:

• Simplifying procurement procedures for state governments
• Allowing hospitals to stock morphine without repeated licensing
• Enabling palliative care access
• Supporting OST programs

Challenges in Clinical Practice

Psychiatrist's Role

• Maintain accurate medical documentation (substance use as illness, not moral failure)
• Advocate for treatment diversion via Section 64-A / Section 71
• Support OST programs, prescribing within legal framework
• Report suspected child abuse when NOWS/parental addiction presents
• Participate in medico-legal process: provide clinical reports on addiction as disease

Mnemonics & Memory Tricks

1. Delirium Tremens Features

2. CAGE Questionnaire

3. Wernicke's Encephalopathy Triad

Alternative: "WOW", Wernicke's = Ophthalmoplegia + Wobbling (ataxia) + Woozy (confusion)

4. Alcohol Withdrawal Timeline: "6-12-24-48-72"

5. Opioid Withdrawal Signs

6. Stages of Change: Prochaska & DiClemente

7. FRAMES: Brief Intervention Components

8. Disulfiram Reaction Features

9. Fetal Alcohol Spectrum: Facial Features

10. Opioid Receptors: "MKD"

11. Naltrexone: Key Clinical Facts

12. Acamprosate: Quick Memory

13. Buprenorphine Pharmacology: "PARTIAL CEILING"

14. Korsakoff's Syndrome Features

15. Nicotine Dependence Treatment Ladder

16. Change Talk: DARN CAT

17. CIWA-Ar Items: "TATPHAAVO"

18. DSM-5 SUD Criteria: 4 Domains

19. Alcohol Metabolism: Sequential Steps

20. Opioid Overdose Triad

High-Yield Comparisons

TABLE 1: Alcohol Withdrawal vs Delirium Tremens vs Alcoholic Hallucinosis

Swipe to compare →

TABLE 2: Disulfiram vs Naltrexone vs Acamprosate

TABLE 3: Methadone vs Buprenorphine in OST

TABLE 4: ICD-11 vs DSM-5 Substance Use Classification

TABLE 5: Opioid Intoxication vs Opioid Withdrawal

TABLE 6: Cannabis-Induced Psychosis vs Primary Psychosis (Schizophrenia)

TABLE 7: Physical Dependence vs Psychological Dependence

TABLE 8: Benzodiazepine Withdrawal vs Alcohol Withdrawal

TABLE 9: Fetal Alcohol Syndrome vs Other Causes of Intellectual Disability

TABLE 10: Stimulant Intoxication vs Stimulant Withdrawal ("Crash")

TABLE 11: AUDIT vs CAGE: Screening Tool Comparison

PYQ Frequency Analysis

SECTION 1: OVERALL TOPIC FREQUENCY MAP

The following analysis categorises SUD subtopics by their historical appearance frequency across Indian PG psychiatry written papers.

SECTION 2: PERENNIAL FAVOURITES: DEEP ANALYSIS

2.1 Alcohol Withdrawal Management

Why it appears every cycle: Core clinical competency. The single topic where a psychiatry postgraduate is expected to demonstrate immediate practical skills.

What examiners test:

• Timeline of withdrawal (6-12-24-48-72 hours framework)
• CIWA-Ar: what it scores, thresholds, symptom-triggered vs fixed-dose
• Benzodiazepine choice and rationale (diazepam vs lorazepam vs oxazepam)
• Thiamine before glucose, rule must be explicitly stated
• DTs: recognition, ICU management
• Relapse prevention pharmacotherapy

Common mistakes that cost marks:

• Mentioning haloperidol as primary treatment for DTs (it is adjunct only, no anticonvulsant effect)
• Not mentioning CIWA-Ar
• Omitting thiamine supplementation protocol
• Confusing the withdrawal seizure timing with DTs onset

Likely question formats:

• "Discuss management of alcohol withdrawal syndrome" [10 marks]
• "Describe delirium tremens, features and management" [10 marks]
• "A 45-year-old male presents with tremors and confusion 48 hours after his last drink. Discuss diagnosis and management" [10 marks]

2.2 Wernicke-Korsakoff Syndrome

Why it appears every cycle: Bridging neurology + psychiatry + addiction. High clinical consequence if missed. Tested in both short and long answers.

What examiners test:

• Wernicke's triad (but note only 10–16% have full triad)
• Pathology (mammillary bodies, dorsomedial thalamus, periaqueductal grey)
• Korsakoff's features: anterograde amnesia, confabulation, insight
• The "thiamine before glucose" rule
• Treatment dosing (200–500 mg IV thiamine)
• Prognosis (25% good, 50% partial, 25% minimal)

Common mistakes:

• Stating the full triad is always present
• Confusing anterograde and retrograde amnesia directionality
• Not distinguishing Korsakoff's from Alzheimer's dementia

Likely question formats:

• "Discuss Wernicke-Korsakoff syndrome" [10 marks]
• "Describe the neuropsychiatric complications of alcohol use disorder" [10 marks, where WKS is expected as a major section]
• Short note: "Korsakoff's psychosis" [5 marks]

2.3 Motivational Interviewing

Why it appears every cycle: MI is now part of standard psychiatry competency frameworks. Examiners see it as testable theory with direct clinical application.

What examiners test:

• MI Spirit (PACE acronym)
• Four processes (Engaging, Focusing, Evoking, Planning)
• OARS (Open questions, Affirmations, Reflective listening, Summaries)
• Change talk: DARN-CAT
• Ambivalence as central concept
• Evidence base (Project MATCH, Cochrane)

Common mistakes:

• Describing MI as "advice giving" (it is explicitly NOT directive advice-giving)
• Confusing MI with Brief Intervention (BI is advice-focused; MI is evocative)
• Not mentioning the Spirit, examiners specifically look for this

Likely question formats:

• "Describe motivational interviewing in the management of substance use disorders" [10 marks]
• "Discuss psychosocial interventions in alcohol dependence" [10 marks, MI expected as main section]
• Short note: "Stages of change and motivational interviewing" [5 marks]

2.4 Stages of Change (Transtheoretical Model)

Why it appears every cycle: Conceptually elegant, well-researched, directly applicable to every clinical encounter with a person who uses substances.

What examiners test:

• 6 stages (PC, C, Prep, Action, Maintenance, Relapse) with definitions
• Stage-matched interventions
• Decisional balance concept
• Spiral model of relapse
• Integration with MI

Likely question formats:

• "Describe the transtheoretical model of behaviour change" [10 marks]
• "Discuss stages of change and their relevance in managing substance use disorders" [10 marks]
• Short note: "Prochaska and DiClemente's model" [5 marks]

2.5 AUDIT and CAGE

Why it appears every cycle: Screening is a core public health and clinical competency. Examiners test both the tool content and the clinical decision-making that follows.

What examiners test:

• CAGE: all 4 questions verbatim (must be written out)
• AUDIT: 3 domains, scoring thresholds (8/15/20)
• AUDIT-C: 3 items, threshold
• Comparison of the two tools
• SBIRT framework (Screening-Brief Intervention-Referral to Treatment)

Likely question formats:

• "Describe screening instruments used in alcohol use disorder" [10 marks]
• "Compare AUDIT and CAGE" [10 marks]
• Short note: "CAGE questionnaire" [5 marks]

SECTION 3: HIGH-FREQUENCY ROTATING TOPICS

3.1 Disulfiram vs Naltrexone vs Acamprosate

Pattern: Appears as either a 10-mark long answer or a 5-mark "compare and contrast."

What to include:

• Mechanism (ALDH inhibition / MOR antagonism / GABA-NMDA modulation)
• Dose for each
• DER features for disulfiram
• Clinical profile (best for whom)
• Contraindications (especially: naltrexone contraindicated in opioid users)

3.2 Delirium Tremens

Pattern: Either as a standalone question or as part of "complications of alcohol withdrawal."

Must-include:

• Clinical features (5 Ds: Delirium, Diaphoresis, Dysautonomia, Dread, Dreams/hallucinations)
• Timing (48–72 hours)
• Mortality (untreated 15–35%; treated <1%)
• Management (IV diazepam, ICU, thiamine, treat precipitants)
• DTs vs alcoholic hallucinosis differentiation

3.3 Opioid Substitution Therapy

Pattern: Appears regularly as either "discuss OST" or "compare methadone and buprenorphine."

Must-include:

• Rationale (harm reduction framework)
• WHO essential medicines status
• Methadone (full agonist) vs buprenorphine (partial agonist + ceiling effect)
• Induction protocol for buprenorphine (COWS ≥8–12)
• Psychosocial components
• Indian DTC context

3.4 Alcoholic Hallucinosis

Pattern: Frequently tested as a short note or as part of "differentials in psychosis."

Key differentiating features from DTs: Clear consciousness, auditory > visual, no autonomic instability, must be stated explicitly.

SECTION 4: RISING TOPICS: INCREASING EXAM FREQUENCY

4.1 Cannabis and Psychosis

Trend: Significant increase in frequency over last 3–5 years, driven by:

• Public policy debates around cannabis decriminalisation
• High-profile international research (Di Forti, EU-GEI study)
• Rising prevalence of cannabis use among Indian youth

What to master:

• Bradford Hill criteria for causality (especially temporality, dose-response, experiment)
• THC:CBD ratio and psychosis risk
• Cannabis-induced psychosis vs schizophrenia differentiation table
• 25–50% conversion to schizophrenia-spectrum figure
• Management: abstinence + antipsychotic + psychoeducation

4.2 NDPS Act Provisions

Trend: Rising sharply, reflects curriculum updates emphasising law, ethics, and policy in psychiatry.

What to master:

• Section 64-A (immunity for voluntary treatment seeking), most clinically relevant
• Section 71 (government treatment centres)
• Section 76 (probation to treatment)
• Small vs large quantity thresholds for heroin, cocaine, cannabis
• 2014 Amendment (essential medicines access)

4.3 Dual Diagnosis

Trend: Increasing, reflects integration of addiction psychiatry with general psychiatry in practice.

What to master:

• Epidemiology (ECA study: 37% AUD with comorbid psychiatric disorder)
• Four pathways (self-medication, substance-induced, common factor, bidirectional)
• Sequential vs parallel vs integrated treatment models
• Integrated treatment as gold standard
• Clozapine in schizophrenia + cannabis use

4.4 Novel Psychoactive Substances

Trend: Included in recent curriculum updates. Examiners testing awareness of emerging substances.

What to master:

• Definition (designed to mimic controlled substances while evading scheduling)
• Categories: synthetic cannabinoids, synthetic cathinones, novel phenethylamines, novel opioids
• Synthetic cannabinoids: full CB1 agonists, more toxic than THC, not detected on standard screens
• Synthetic cathinones ("bath salts"): stimulant + psychosis
• Clinical approach: supportive management, no specific antidotes

4.5 Neonatal Abstinence Syndrome / NOWS

Trend: Rising with increased emphasis on perinatal psychiatry.

What to master:

• Finnegan Scale (categories: CNS, metabolic, GI, respiratory)
• Pharmacological treatment threshold (Finnegan ≥8 on two consecutive assessments)
• First-line treatment: oral morphine
• Buprenorphine-exposed NOWS vs methadone-exposed NOWS (buprenorphine = milder, shorter)
• Non-pharmacological: kangaroo care, breastfeeding, low stimulation

SECTION 5: QUESTION TYPE FREQUENCY BY FORMAT

SECTION 6: TOPIC PRIORITY MATRIX

Swipe to compare →

SECTION 7: HIGH-YIELD ANSWER-WRITING FRAMEWORK

The "DEMC" Answer Structure for Management Questions

Every management question should follow:

• Define, 2–3 sentences on the condition being managed
• Evaluate, assessment tools, severity grading, examination findings
• Manage, step-by-step pharmacological + non-pharmacological, complications
• Consolidate, relapse prevention, prognosis, follow-up

The "MAPS" Answer Structure for Comparison Questions

• Mechanism, compare mechanisms
• Application, clinical use, dosing, indication
• Problems, contraindications, side effects
• Summary table, always end with or include a comparison table

Writing Tables Under Exam Conditions

• Draw the table first (skeleton: 3 columns × 6–8 rows)
• Fill rows from memory (mechanism, dose, side effects, contraindications)
• Label rows and columns clearly
• Add a pearl box after the table

SECTION 8: PREDICTED HIGH-PROBABILITY QUESTIONS: NEXT EXAM CYCLE

Based on topic rotation patterns and recent literature citations in Indian psychiatry curricula:

SECTION 9: EXAMINER CHECKLIST: WHAT EARNS MARKS

Reconstructed from answer key patterns across multiple exam cycles:

Alcohol Withdrawal Management (10 marks)

• [ ] Timeline stated (6-12-24-48-72 framework)
• [ ] CIWA-Ar mentioned with scoring threshold
• [ ] Thiamine before glucose stated explicitly
• [ ] Benzodiazepine named with dose and route
• [ ] DTs differentiated from uncomplicated withdrawal
• [ ] Relapse prevention agents mentioned
• [ ] Psychosocial component mentioned

Motivational Interviewing (10 marks)

• [ ] MI Spirit (PACE) defined
• [ ] Four processes named
• [ ] OARS skills described
• [ ] Change talk (DARN-CAT) mentioned
• [ ] Ambivalence as central concept
• [ ] Evidence base (Project MATCH or Cochrane)
• [ ] Limitation or appropriate context

Wernicke-Korsakoff (10 marks)

• [ ] Thiamine deficiency mechanism explained
• [ ] Wernicke's triad stated
• [ ] "Only 10–16% have full triad" stated
• [ ] Pathological sites: mammillary bodies, dorsomedial thalamus
• [ ] Treatment: IV thiamine before glucose, dose stated
• [ ] Korsakoff's: anterograde amnesia, confabulation, insight absent
• [ ] Prognosis percentages given

Quick Review

Vignette 1: The Morning Tremor

Case: Ramesh, a 48-year-old accountant, is brought to the emergency department by his wife at 8 AM. She reports he had his last drink at 10 PM the previous night. He appears sweaty, tremulous, and agitated. His heart rate is 112 bpm, BP 158/96 mmHg, temperature 37.6°C. He is oriented but anxious. He says he has been drinking 12–15 units of alcohol daily for the past 8 years. His CIWA-Ar score is assessed as 14.

Q1. What is the diagnosis? Justify using ICD-11 criteria.

Answer:

Ramesh has Alcohol Withdrawal Syndrome (ICD-11: 6C40.5, Alcohol withdrawal, uncomplicated).

Justification:

• Established pattern of heavy alcohol use (8 years, 12–15 units/day = physiological dependence)
• Recent cessation/reduction (last drink 10 hours ago)
• Classic withdrawal features within the expected 6–12 hour window: tremor, tachycardia (112), hypertension (158/96), diaphoresis, anxiety, agitation
• CIWA-Ar 14 = moderate severity (threshold 8–15)
• Consciousness clear, excludes delirium tremens at this stage

Q2. What is the CIWA-Ar score of 14 telling you, and how does it guide management?

Answer:

CIWA-Ar 14 = moderate withdrawal severity. This score indicates:

• Pharmacological treatment is required (threshold for treatment ≥8)
• Symptom-triggered benzodiazepine protocol appropriate
• Does not yet meet threshold for ICU/HDU (>20)
• Oral route likely adequate if patient can cooperate

Management based on CIWA-Ar 14:

1. Oral diazepam 20 mg now → reassess in 1 hour
2. If CIWA-Ar still ≥8 at 1 hour → repeat 10–20 mg
3. Thiamine 100–200 mg IV/IM before any IV glucose
4. Monitor vitals 2-hourly; CIWA-Ar 4-hourly
5. Target CIWA-Ar <8 before stepping down

Q3. What are the risk factors in this case for progression to delirium tremens?

Answer:

Risk factors in Ramesh's case:

• Long duration and high quantity of use (8 years, 12–15 units/day): chronic neuroadaptation
• Hypertension already at presentation: suggests significant autonomic activation
• Moderate CIWA-Ar at 10 hours: may worsen over next 24–48 hours

General DTs risk factors to mention in exam: prior DTs/seizures, age >65, concurrent illness, benzodiazepine co-dependence, severe malnutrition, prolonged use.

Vignette 2: The Terrifying Insects

Case: Priya, a 52-year-old retired teacher with a 20-year history of alcohol dependence, is admitted on Day 3 after her last drink. She is severely agitated, diaphoretic, and disoriented to time and place. She is screaming that insects are crawling over her body and that small men are trying to harm her. Her temperature is 39.2°C, HR 134 bpm, BP 172/104 mmHg. Her husband reports she had a witnessed seizure at home 12 hours ago before admission.

Q1. Identify the syndrome and list its diagnostic features.

Answer:

Priya has Delirium Tremens (ICD-11: 6C40.6, Alcohol withdrawal with delirium).

Diagnostic features present:

• Delirium: disorientation to time and place, grossly disturbed consciousness
• Visual hallucinations: insects on body (tactile + visual), Lilliputian figures ("small men")
• Severe autonomic instability: temperature 39.2°C (hyperthermia), HR 134 (tachycardia), BP 172/104 (hypertension), diaphoresis
• Timing: 72 hours post-last drink (DTs peak: 48–72 hours)
• Prior seizure: withdrawal seizure preceded DTs (as expected, seizures peak at 24–48h, DTs at 48–72h)

Q2. Outline the immediate management priorities.

Answer:

Q3. What is the prognosis and what determines it?

Answer:

• Untreated DTs mortality: 15–35%
• With treatment: <1%
• Most common cause of death: cardiovascular (arrhythmia, not seizure)

Poor prognostic factors:

• Concurrent infection / sepsis
• Severe hyperthermia >40°C
• Underlying liver failure (hepatic encephalopathy may compound)
• Delayed presentation (>72 hours of untreated DTs)
• Aspiration pneumonia
• Prior DTs (kindling)

Vignette 3: The Man Who Hears Voices but Knows It

Case: Suresh, a 41-year-old businessman, presents with his wife at 11 PM, 18 hours after his last drink. He is agitated but answers questions correctly, knows the date and where he is. He says he has been hearing two men's voices for the past 4 hours talking about him, calling him a thief and saying they will hurt him. He is visibly frightened. Vitals: HR 88, BP 130/82, afebrile. He has been drinking 8–10 units daily for the past 6 years.

Q1. What is the diagnosis? Distinguish it from delirium tremens.

Answer:

Suresh has Alcoholic Hallucinosis (ICD-11: 6C40.70, Substance-induced psychotic disorder).

Key diagnostic features:

• Onset 12–24 hours after last drink (hallucinosis window)
• Clear consciousness: oriented, answering correctly, knows date and place
• Auditory hallucinations (voices): threatening, accusatory, characteristic content
• Intact sensorium: no delirium
• Mild/absent autonomic features: HR 88, BP 130/82, afebrile

Distinction from DTs:

Swipe to compare →

Q2. What is the treatment and expected course?

Answer:

Treatment:

1. Benzodiazepines: for co-occurring withdrawal features (even mild), diazepam 10 mg oral + monitor
2. Antipsychotics: haloperidol 5 mg oral/IM → for psychotic symptoms (voices)
3. Monitor: CIWA-Ar to detect escalating withdrawal
4. Safe environment: low stimulation, orientation cues, family presence
5. Thiamine: oral thiamine 100 mg (prophylactic against Wernicke's)

Expected course:

• Most cases resolve within hours to days with abstinence and treatment
• Rare persistence beyond 2 weeks
• If persists >1 month after abstinence → reassess diagnosis → primary psychotic disorder?

Q3. What is the risk of progression to DTs in this patient?

Answer:

Moderate risk:

• He is only 18 hours post-last drink, DTs peak is 48–72 hours, still 30–54 hours away
• Current mild autonomic state is reassuring but can change
• Risk factors present: 6-year heavy use
• Monitor CIWA-Ar every 4 hours over the next 48 hours
• Escalation protocol: if CIWA-Ar rises >15, upgrade to IV route and consider HDU

Vignette 4: The Unconscious Young Man

Case: Vikram, a 24-year-old, is brought by friends to the emergency department unconscious. Friends report he "injected something" 30 minutes ago. On examination: deeply unconscious (GCS 6), respiratory rate 6 breaths/minute, pupils 2 mm bilaterally (pinpoint), cyanotic, HR 52, BP 90/60.

Q1. What is the most likely diagnosis and the diagnostic triad?

Answer:

Opioid overdose (ICD-11: 6C43.10, Opioid intoxication with overdose).

The diagnostic triad of opioid overdose:

1. Miosis (pinpoint pupils, 2 mm), pathognomonic when bilateral
2. CNS depression (GCS 6, stupor/coma)
3. Respiratory depression (RR 6, life-threatening; normal is 12–20)

Additional findings consistent: bradycardia, hypotension, cyanosis (from hypoxia).

Q2. Outline immediate emergency management.

Answer:

Q3. Vikram recovers and is willing to talk. What is the next step in management?

Answer:

This is a "teachable moment", the overdose has increased his readiness to engage.

Immediate next steps:

1. Motivational interview: brief MI while the experience is fresh; assess stage of change
2. Psychoeducation on overdose risk: tolerance reduction after any abstinence period (even hours); risks of resuming at previous dose
3. Take-home naloxone: prescribe and train Vikram AND his friends on administration
4. Harm reduction: if not ready for abstinence, sterile needles, wound care, BBV testing (HIV, HBsAg, HCV)
5. OST referral: offer buprenorphine/naloxone induction, if COWS ≥8–12, can begin same day
6. Social assessment: housing, support, NDPS legal status

Vignette 5: The Student Who Stopped Making Sense

Case: Kaveri, a 19-year-old engineering student, is brought by her parents after a 3-week history of increasingly disorganised behaviour, social withdrawal, and talking about "being monitored by satellites." Her parents report she began smoking cannabis regularly 8 months ago and was using it daily for the last 3 months. Urine drug screen: THC positive. She denies alcohol or other drug use. Family history: paternal uncle has schizophrenia.

Q1. What are the two differential diagnoses and how would you approach them?

Answer:

The two primary differential diagnoses:

1. Cannabis-induced psychotic disorder (ICD-11: 6C41.70)
2. Schizophrenia, first episode (ICD-11: 6A20.0)

Diagnostic approach:

Q2. What features increase the probability of conversion to a primary psychotic disorder?

Answer:

High-risk features for conversion to schizophrenia-spectrum disorder:

Kaveri has 3–4 identified risk factors → conversion probability elevated (~40–50% at 5 years).

Q3. What is the initial pharmacological and psychosocial management?

Answer:

Pharmacological:

• Antipsychotic: low-dose risperidone 1–2 mg/day or olanzapine 5 mg/day
• Duration: minimum 3–6 months; reassess at 6 months with confirmed abstinence
• If psychosis persists beyond 6 months of abstinence: long-term antipsychotic per first-episode schizophrenia guidelines

Psychosocial:

• Psychoeducation: cannabis-psychosis link, evidence-based, non-blaming communication to Kaveri and family
• Motivational Interviewing: she is likely in contemplation or preparation stage (the episode has created ambivalence)
• CBT-p: cognitive behavioural therapy for psychosis, addresses both residual symptoms and cannabis use
• Family education: high expressed emotion management; avoid blame; support abstinence without coercion

Vignette 6: The Executive on Benzodiazepines

Case: Meena, a 44-year-old corporate executive, presents requesting a refill of clonazepam 2 mg at night, which she has been prescribed by her GP for insomnia for the past 4 years. She reports that if she misses even one dose, she gets "unbearable anxiety, heart racing, and can't sleep at all." She has tried stopping twice and once had a brief convulsion. She denies alcohol use. She wants to stop but says she "can't function without it."

Q1. What is the diagnosis? Apply ICD-11 criteria.

Answer:

Benzodiazepine dependence (ICD-11: 6C44.2, Dependence on sedative, hypnotic, or anxiolytic, clonazepam).

ICD-11 criteria met (3 of 7 required):

1. Impaired control: has tried to stop twice unsuccessfully ("can't function without it")
2. Salience: dependence on clonazepam for sleep and anxiety management
3. Tolerance: likely, 4 years of regular use; may need dose increases over time
4. Withdrawal: definite, anxiety, tachycardia, insomnia on missing dose; convulsion on previous cessation (severe withdrawal)
5. Continued use despite harm: psychological and likely occupational impairment

Q2. Outline a safe detoxification plan.

Answer:

Clonazepam 2 mg/night = approximately diazepam 20 mg equivalent (clonazepam 0.5 mg ≈ diazepam 5 mg).

Step 1, Switch to diazepam equivalent:

• Convert to diazepam 20 mg nocte (or split 10 mg AM / 10 mg PM for comfort)
• Diazepam: long-acting, smooth plasma levels, fewer interdose symptoms

Step 2, Slow taper:

• Reduce by 10% every 1–2 weeks
• At 10 mg diazepam: slow to 5% per week
• Total duration: 6–12 months (this is NOT a 10-day alcohol detox equivalent)

Step 3, Monitor closely:

• Weekly review initially; fortnightly when stable
• CIWA-B (benzodiazepine withdrawal scale) or symptom diary
• Educate on withdrawal seizure risk, do NOT miss doses; do NOT abrupt stop

Step 4, Address underlying anxiety/insomnia:

• SSRI/SNRI for anxiety disorder (start during taper)
• Cognitive Behavioural Therapy for Insomnia (CBT-I)
• Sleep hygiene

Step 5, Given prior seizure:

• Slower taper rate; consider neurological consultation
• Seizure precautions during taper (no driving, no heights, supervision)

Q3. What psychosocial interventions support BZD discontinuation?

Answer:

• CBT: addresses the anxiety and catastrophic thinking that drives BZD use; most evidence-based
• CBT-I (specifically for insomnia): stimulus control, sleep restriction, relaxation, as effective as BZD for insomnia long-term
• Psychoeducation: explain physiological dependence = addiction; reduce shame; explain the taper rationale
• Motivational Interviewing: Meena is in preparation stage (she WANTS to stop but feels she can't), appropriate for planning intervention
• Mindfulness-based stress reduction (MBSR): supports anxiety management without medication

Vignette 7: The Truck Driver

Case: Raju, a 35-year-old long-distance truck driver, is referred by occupational health after a routine health check. His AUDIT score is 18. He drinks every evening and on long trips uses 1–2 units during driving "to stay calm." He has never attempted to stop. He becomes defensive when the occupational health nurse mentions his drinking. His wife has complained about his drinking but he says "she's overreacting."

Q1. What stage of change is Raju in, and what intervention is appropriate?

Answer:

Raju is in Precontemplation (possibly early Contemplation).

Evidence for precontemplation:

• Denies problem ("she's overreacting")
• Never attempted to stop
• Defensive when drinking mentioned
• No expressed desire to change

However, his AUDIT of 18 (probable dependence range), occupational health referral, and wife's complaints suggest he is receiving multiple external signals, he may be early Contemplation.

Appropriate intervention: Brief Motivational Interviewing (not advice-giving; not confronting denial)

MI strategy for precontemplation:

1. Avoid argument: rolling with resistance, "It sounds like this is an area where you and your wife see things differently."
2. Raise doubt gently: "I'm wondering if it's okay to share with you what I'm noticing in your health results?"
3. Decisional balance: "What are the good things about drinking for you? What are the not-so-good things?"
4. Importance ruler: "On a scale of 0–10, how important is it to you right now to make a change? ... What would need to happen for that number to go up?"
5. Affirm: "It takes something to come in and have this conversation."

Q2. Raju's AUDIT score is 18. What does this indicate and what screening + intervention pathway should follow?

Answer:

AUDIT 18 = Probable alcohol dependence (threshold ≥16 suggests probable dependence; ≥20 definite).

SBIRT pathway:

• Screening: done (AUDIT 18) → positive
• Brief Intervention: 5–15 minute structured session; FRAMES components; offered today
• Referral to Treatment: AUDIT >15 = referral to specialist (addiction psychiatrist / de-addiction centre) recommended; offer actively today

Occupational context, additional concerns:

• Driving under influence (1–2 units while driving): legal and safety issue
• Fitness to drive: occupational health must formally assess
• Mandatory notification: occupational physician may have duty to notify licensing authority depending on jurisdiction
• NDPS Act: alcohol not under NDPS but road safety law applies

Q3. What brief intervention content is most appropriate for Raju?

Answer:

FRAMES-structured brief intervention (15 minutes):

Vignette 8: The New Mother on Methadone

Case: Ananya, a 29-year-old, presents at 14 weeks of pregnancy. She discloses she has been using heroin IV daily for 3 years and is currently using 0.5 g/day. She is also HIV negative. She is frightened about what her drug use means for her baby. She asks if she should stop immediately to protect the foetus.

Q1. What is the appropriate response to her question about stopping?

Answer:

Ananya should NOT be advised to stop abruptly or rapidly. This is a critical clinical error.

Rationale:

• Abrupt opioid cessation in pregnancy → fetal withdrawal → fetal distress, preterm labour, spontaneous abortion risk (especially in first and second trimester)
• The foetus has developed opioid dependence in utero; abrupt withdrawal is hazardous to the foetus
• Maternal abstinence syndrome → maternal relapse → illicit opioid use → uncontrolled dosing, contaminants, needle sharing, all far more dangerous
• OST (methadone or buprenorphine) is the standard of care in pregnancy

Q2. Which OST agent is preferred in pregnancy and why?

Answer:

Both are acceptable. Methadone historically preferred; buprenorphine increasingly supported based on MOTHER trial (Jones 2010): buprenorphine-exposed neonates had significantly shorter NOWS duration and needed less morphine.

Q3. Ananya is started on buprenorphine. Her baby is born at 38 weeks. The neonatologist calls you asking about neonatal management. What are the key points?

Answer:

Key neonatal management points:

1. Expected NOWS: buprenorphine-exposed neonates, onset 12–48 hours, typically milder than methadone
2. Assessment: Finnegan Neonatal Abstinence Scoring System (FNASS) every 4 hours
3. Pharmacological threshold: Finnegan ≥8 on two consecutive assessments → pharmacological treatment
4. First-line treatment: Oral morphine (0.03–0.1 mg/kg/dose every 3–4 hours, titrated to Finnegan <8)
5. Non-pharmacological: Skin-to-skin, breastfeeding (Ananya is HIV negative, on stable OST, no other drug use → breastfeeding encouraged), low stimulation, swaddling
6. Breastfeeding: strongly encouraged, buprenorphine passes into breast milk in minimal amounts; breastfeeding significantly reduces NOWS severity and duration
7. Discharge planning: ensure Ananya has robust social support; postnatal depression screening; continued OST; community health worker link

Vignette 9: The Reluctant Abstainer

Case: Mohan, a 58-year-old retired civil servant, has completed alcohol detoxification 2 weeks ago. He is now in the relapse prevention phase. He is abstinent but does not feel well, he is anxious, not sleeping, and reports persistent low-grade craving. He says "I feel worse sober than I ever did drunk." He is asking for something to help.

Q1. What syndrome is he experiencing and what is its mechanism?

Answer:

Mohan is experiencing Protracted Alcohol Withdrawal Syndrome (also: Post-Acute Withdrawal Syndrome, PAWS).

Features consistent:

• Persistent anxiety, insomnia, and craving beyond the acute 5–7 day withdrawal window
• Anhedonia/dysphoria ("feel worse sober")
• Onset 2 weeks post-detox, consistent with protracted course

Mechanism: Allostatic dysregulation (Koob model)

• Chronic alcohol → GABA-A downregulation + NMDA upregulation → homeostatic set point shifted
• Even after acute withdrawal resolves, the glutamate-GABA balance takes weeks to months to normalise
• Protracted low-level CNS excitability → anxiety, sleep disruption, craving
• Mesolimbic dysphoria: chronic alcohol → blunted dopaminergic reward → everything feels flat without alcohol

Q2. Which relapse prevention pharmacotherapy is best suited to Mohan, and why?

Answer:

Acamprosate is the optimal choice for Mohan.

Rationale:

Dose: 666 mg TID (check renal function first, CrCl >30 required).

Additional adjuncts:

• Low-dose SSRI (sertraline 50 mg) if anxiety is prominent
• Sleep hygiene counselling + melatonin for insomnia
• Ongoing MI/CBT sessions
• Mutual aid (AA) referral

Q3. Mohan asks if he will always feel this way. What do you tell him?

Answer:

Evidence-based, hopeful, honest counselling:

• Protracted withdrawal symptoms typically improve over 3–12 months with sustained abstinence
• Brain neuroplasticity allows recovery of GABA-glutamate balance and dopaminergic reward systems
• Mood, sleep, and cognitive function generally improve, but recovery is not linear
• Acamprosate helps reduce the internal discomfort during this recovery phase
• Abstinence itself is the most powerful "medication", each day sober supports neurobiological recovery
• Some cognitive impairment (attention, memory) may persist longer, typically 12–24 months to maximum recovery
• Realistic optimism: "Most people who stay abstinent at 3 months report significant improvement by 6–12 months."

Vignette 10: The Teenager with Strange Behaviour

Case: Arun, a 16-year-old schoolboy, is brought by his parents. He was found unconscious in his room with an aerosol can and a plastic bag. He regained consciousness within 20 minutes. His parents note this has happened before. He appears disoriented and has mild nystagmus on examination. No other substances on urine drug screen. Neurological examination: mild cerebellar signs.

Q1. What is the substance involved and what are the clinical features of its misuse?

Answer:

Arun is misusing inhalants (specifically aerosol, likely toluene-containing product, e.g., deodorant, solvent, paint thinner).

Inhalant use disorder (ICD-11: 6C4B, Disorders due to volatile inhalants).

Clinical features:

• Acute intoxication: euphoria, dizziness, disorientation, nystagmus, slurred speech, ataxia; brief (minutes to hours), consistent with Arun's episode
• Mechanism: toluene and similar volatile compounds → CNS depression (GABA-A + NMDA effects; general anaesthetic-like)
• "Sudden sniffing death": sensitisation of myocardium to catecholamines → ventricular fibrillation; risk highest with fluorocarbons (aerosols, refrigerants)
• Chronic complications: cerebellar atrophy (explains Arun's cerebellar signs), white matter demyelination, cognitive decline, tubular nephropathy, hepatotoxicity
• Pattern: adolescents; socioeconomically vulnerable populations; cheap and accessible

Q2. How prevalent is inhalant misuse in India and what are the common substances?

Answer:

India-specific context:

• Fevicol (white glue), Dendrite, petrol, nail polish remover, correction fluid, aerosol sprays, whitener
• Particularly prevalent among street children and adolescents in urban areas
• Often the first substance tried (accessible, cheap, no legal barrier for purchase)
• Maharashtra, Delhi, Bangalore: significant street child populations with inhalant use
• No reliable national prevalence data; estimated 2–5% of substance use presentations in adolescent psychiatry

Q3. What is the management approach?

Answer:

No approved pharmacotherapy for inhalant use disorder. Management is psychosocial.

Acute:

• Supportive, oxygen, monitor cardiac rhythm (defibrillator available)
• Avoid adrenaline (VF risk)
• Treat any hypoxia or arrhythmia

Longer-term:

• Individual CBT: coping skills, trigger identification
• Family therapy: especially with adolescents, family engagement crucial
• Motivational Interviewing: adapted for adolescent developmental stage
• School re-engagement: often dropout precedes inhalant use
• Social work: address poverty, homelessness, family violence (root causes)
• Residential rehabilitation: for severe, homeless cases
• Neuropsychological assessment: if cerebellar signs present (Arun), document baseline, monitor for progression

Vignette 11: The Man Who Changed After Drinking

Case: Laxman, a 50-year-old, is brought by police following an assault. His wife reports he had 2 units of alcohol (a single peg of whisky and half a beer) approximately 30 minutes before the assault. She says he is a completely different person when he drinks, aggressive, paranoid, violent, and then has no memory of the episode. He is calm and cooperative now. His baseline is mild-mannered. BAC at time of arrest was 30 mg/dL (well below legal limit of 80 mg/dL in most Indian states).

Q1. What is the diagnosis and what are its features?

Answer:

Pathological intoxication (Alcohol-Induced Persisting Amnestic Disorder / Alcohol Idiosyncratic Intoxication, ICD-10 term; absorbed into "Other specified alcohol-related disorder" in DSM-5 and ICD-11).

Features:

• Extreme, disproportionate behavioural change (violence, aggression) after a small amount of alcohol
• Amount consumed grossly disproportionate to the behavioural response (2 units → assault vs no effect in most people)
• BAC low (30 mg/dL), not consistent with typical intoxication aggression at this level
• Complete or near-complete amnesia for the episode
• Behaviour out of character with baseline personality

Proposed mechanism:

• Temporal lobe disinhibition / epileptic equivalent in susceptible individuals
• Possibly relates to alcohol-induced paradoxical disinhibition
• Uncommon and diagnostically controversial, must exclude: hypoglycaemia, head injury, co-ingested substances, factitious/malingering

Q2. What investigations would clarify the diagnosis?

Answer:

Q3. What advice do you give regarding future alcohol use?

Answer:

Clear, unambiguous advice:

• Total abstinence from alcohol, the only safe recommendation
• Even small amounts are dangerous in this individual
• If he continues drinking, future episodes are highly likely
• Medico-legal implications: if charged with assault in future under similar circumstances, history of pathological intoxication may affect culpability but does not excuse behaviour
• If epileptic mechanism confirmed: anticonvulsants (carbamazepine) may reduce episodes but do NOT permit drinking
• Family education: wife must know to prevent access to alcohol and to call emergency services if early signs appear

Vignette 12: The Dual Diagnosis Dilemma

Case: Shalini, a 32-year-old woman with a 5-year history of bipolar disorder type I (currently on lithium 900 mg/day, stable), presents with a 2-month history of increasing cannabis use (daily, 3–4 times/day) following a stressful job loss. She reports that cannabis "calms her down" and prevents mood episodes. Her most recent YMRS is 8 (subclinical hypomania). She has started skipping lithium doses.

Q1. Identify the clinical and diagnostic issues.

Answer:

Multiple overlapping issues:

Q2. How does cannabis affect bipolar disorder course?

Answer:

Established adverse effects of cannabis in bipolar disorder:

• More frequent mood episodes: both manic and depressive
• Greater severity of episodes: particularly mania
• Worse functional outcomes: employment, relationships
• Reduced medication adherence: cannabis users less likely to take mood stabilisers consistently (as in Shalini's case)
• Mania switching risk: THC is psychotomimetic and can precipitate manic or mixed states
• Reduced lithium efficacy: some evidence that cannabis undermines pharmacological stabilisation
• Suicidality: cannabis use associated with increased suicidal ideation in bipolar disorder

Q3. Outline an integrated treatment plan for Shalini.

Answer:

Integrated dual diagnosis treatment (not sequential):

Pharmacological:

• Reinstate lithium adherence, psychoeducation + pill organiser + support
• Consider lithium level check (low level may be contributing to subclinical hypomania)
• Consider valproate add-on if cannabis-induced instability difficult to control (better evidence for mixed states)
• No approved pharmacotherapy for cannabis use disorder; no agent to add

Psychosocial:

• Integrated CBT: addresses both bipolar cognitions AND cannabis use, same therapist, same framework
• Motivational Interviewing: ambivalence is clear (she believes cannabis helps; evidence says it harms), decisional balance + personalised feedback on bipolar-cannabis interaction
• Psychoeducation (bipolar + cannabis): the "calming" effect is short-term, tolerance-developing; over time cannabis worsens her condition
• Relapse prevention: identify triggers for both mood episodes and cannabis use; overlapping coping strategy development
• Sleep hygiene: cannabis disrupts sleep architecture (reduces REM); poor sleep = major bipolar trigger
• Social support: job loss addressed; vocational rehabilitation; family education

Monitoring:

• Mood diary + cannabis diary simultaneously
• YMRS monthly
• Lithium levels every 3 months
• Target: cannabis reduction → abstinence → mood stability → functional recovery